Evidence map›Paper›PMID 37245005›Full record

ArticleBMC medical research methodology2023

Cluster analysis of angiotensin biomarkers to identify antihypertensive drug treatment in population studies.

Maeregu Woldeyes Arisido, Luisa Foco, Robin Shoemaker, Roberto Melotti, Christian Delles, Martin Gögele, Stefano Barolo, Stephanie Baron, Michel Azizi, Anna F Dominiczak and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC medical research methodology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Clinical and Metabolic Signatures ofKidney international reports · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Maeregu Woldeyes ArisidoInstitute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Via Volta 21, 39100, Bolzano, Italy. maeregu.arisido@fht.org.
Luisa FocoInstitute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Via Volta 21, 39100, Bolzano, Italy.
Robin ShoemakerDepartment of Dietetics and Human Nutrition, University of Kentucky, Lexington, USA.
Roberto MelottiInstitute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Via Volta 21, 39100, Bolzano, Italy.
Christian DellesSchool of Cardiovascular and Metabolic Health , University of Glasgow, Glasgow, UK.
Martin GögeleInstitute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Via Volta 21, 39100, Bolzano, Italy.
Stefano BaroloHospital of Schlanders/Silandro, Schlanders/Silandro, Italy.
Stephanie BaronNational Institute of Health and Medical Research (Inserm), Paris, France.
Michel AziziNational Institute of Health and Medical Research (Inserm), Paris, France.
Anna F DominiczakSchool of Cardiovascular and Metabolic Health , University of Glasgow, Glasgow, UK.
Maria-Christina ZennaroNational Institute of Health and Medical Research (Inserm), Paris, France.
Peter P PramstallerInstitute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Via Volta 21, 39100, Bolzano, Italy.
Marko PoglitschAttoquant Diagnostics, Vienna, Austria.
Cristian PattaroInstitute for Biomedicine (affiliated to the University of Lübeck), Eurac Research, Via Volta 21, 39100, Bolzano, Italy. cristian.pattaro@eurac.edu.
Institute for Biomedicine · ITInserm · FRUniversity of Glasgow · GBEurac Research · ITUniversity of Kentucky · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe recent progress in molecular biology generates an increasing interest in investigating molecular biomarkers as markers of response to treatments. The present work is motivated by a study, where the objective was to explore the potential of the molecular biomarkers of renin-angiotensin-aldosterone system (RAAS) to identify the undertaken antihypertensive treatments in the general population. Population-based studies offer an opportunity to assess the effectiveness of treatments in real-world scenarios. However, lack of quality documentation, especially when electronic health record linkage is unavailable, leads to inaccurate reporting and classification bias.

methodWe present a machine learning clustering technique to determine the potential of measured RAAS biomarkers for the identification of undertaken treatments in the general population. The biomarkers were simultaneously determined through a novel mass-spectrometry analysis in 800 participants of the Cooperative Health Research In South Tyrol (CHRIS) study with documented antihypertensive treatments. We assessed the agreement, sensitivity and specificity of the resulting clusters against known treatment types. Through the lasso penalized regression, we identified clinical characteristics associated with the biomarkers, accounting for the effects of cluster and treatment classifications.

resultsWe identified three well-separated clusters: cluster 1 (n = 444) preferentially including individuals not receiving RAAS-targeting drugs; cluster 2 (n = 235) identifying angiotensin type 1 receptor blockers (ARB) users (weighted kappa κ

conclusionsUnsupervised clustering of angiotensin-based biomarkers is a viable technique to identify individuals on specific antihypertensive treatments, pointing to a potential application of the biomarkers as useful clinical diagnostic tools even outside of a controlled clinical setting.

Indexed as

AngiotensinsAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiomarkersCluster AnalysisHumansAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsAntihypertensive AgentsBiomarkersAldosteroneAngiotensinAntihypertensive drugsCHRIS studyCluster analysisLasso regression

Identifiers

PMID37245005
PMCPMC10224304
OpenAlexW4378532947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.